Community interactions govern host-switching with implications for host–parasite coevolutionary history

por Harbison, Christopher W., Clayton, Dale H.
Publicado 2011

Diversity and Heterogeneity of Epibiotic Bacterial Communities on the Marine Nematode Eubostrichus dianae

por Polz, Martin F., Harbison, Christopher, Cavanaugh, Colleen M.
Publicado 1999

Isolation, Pure Culture, and Characterization of “Candidatus Arsenophonus arthropodicus,” an Intracellular Secondary Endosymbiont from the Hippoboscid Louse Fly Pseudolynchia canar...

por Dale, Colin, Beeton, Michael, Harbison, Christopher, Jones, Tait, Pontes, Mauricio
Publicado 2006

Reconstructing dynamic regulatory maps

por Ernst, Jason, Vainas, Oded, Harbison, Christopher T, Simon, Itamar, Bar-Joseph, Ziv
Publicado 2007

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurren...

por Hellmann, Matthew, Ramalingam, Suresh, Reck, Martin, O'Byrne, Ken, Paz-Ares, Luis, Harbison, Christopher T, Bhagavatheeswaran, Prabhu, Nathan, Faith, Brahmer, Julie
Publicado en J Immunother Cancer (2015)

Remodeling of Yeast Genome Expression in Response to Environmental Changes

por Causton, Helen C., Ren, Bing, Koh, Sang Seok, Harbison, Christopher T., Kanin, Elenita, Jennings, Ezra G., Lee, Tong Ihn, True, Heather L., Lander, Eric S., Young, Richard A.
Publicado 2001

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

por Omuro, Antonio, Vlahovic, Gordana, Lim, Michael, Sahebjam, Solmaz, Baehring, Joachim, Cloughesy, Timothy, Voloschin, Alfredo, Ramkissoon, Shakti H, Ligon, Keith L, Latek, Robert, Zwirtes, Ricardo, Strauss, Lewis, Paliwal, Prashni, Harbison, Christopher T, Reardon, David A, Sampson, John H
Publicado en Neuro Oncol (2018)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

por Janjigian, Yelena Y., Bendell, Johanna, Calvo, Emiliano, Kim, Joseph W., Ascierto, Paolo A., Sharma, Padmanee, Ott, Patrick A., Peltola, Katriina, Jaeger, Dirk, Evans, Jeffry, de Braud, Filippo, Chau, Ian, Harbison, Christopher T., Dorange, Cecile, Tschaika, Marina, Le, Dung T.
Publicado en J Clin Oncol (2018)

Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Co...

por Trippett, Tanya M., Herzog, Cynthia, Whitlock, James A., Wolff, Johannes, Kuttesch, John, Bagatell, Rochelle, Hunger, Stephen P., Boklan, Jessica, Smith, Amy A., Arceci, Robert J., Katzenstein, Howard M., Harbison, Christopher, Zhou, Xiaofei, Lu, Haolan, Langer, Christiane, Weber, Martin, Gore, Lia
Publicado en J Clin Oncol (2009)

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

por Gettinger, Scott, Rizvi, Naiyer A., Chow, Laura Q., Borghaei, Hossein, Brahmer, Julie, Ready, Neal, Gerber, David E., Shepherd, Frances A., Antonia, Scott, Goldman, Jonathan W., Juergens, Rosalyn A., Laurie, Scott A., Nathan, Faith E., Shen, Yun, Harbison, Christopher T., Hellmann, Matthew D.
Publicado en J Clin Oncol (2016)

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

por Rizvi, Naiyer A., Hellmann, Matthew D., Brahmer, Julie R., Juergens, Rosalyn A., Borghaei, Hossein, Gettinger, Scott, Chow, Laura Q., Gerber, David E., Laurie, Scott A., Goldman, Jonathan W., Shepherd, Frances A., Chen, Allen C., Shen, Yun, Nathan, Faith E., Harbison, Christopher T., Antonia, Scott
Publicado en J Clin Oncol (2016)

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

por Snyder, Alexandra, Makarov, Vladimir, Merghoub, Taha, Yuan, Jianda, Zaretsky, Jesse M., Desrichard, Alexis, Walsh, Logan A., Postow, Michael A., Wong, Phillip, Ho, Teresa S., Hollmann, Travis J., Bruggeman, Cameron, Kannan, Kasthuri, Li, Yanyun, Elipenahli, Ceyhan, Liu, Cailian, Harbison, Christopher T., Wang, Lisu, Ribas, Antoni, Wolchok, Jedd D., Chan, Timothy A.
Publicado en N Engl J Med (2014)

Transcriptional regulatory code of a eukaryotic genome

por Harbison, Christopher T., Gordon, D. Benjamin, Lee, Tong Ihn, Rinaldi, Nicola J., Macisaac, Kenzie D., Danford, Timothy W., Hannett, Nancy M., Tagne, Jean-Bosco, Reynolds, David B., Yoo, Jane, Jennings, Ezra G., Zeitlinger, Julia, Pokholok, Dmitry K., Kellis, Manolis, Rolfe, P. Alex, Takusagawa, Ken T., Lander, Eric S., Gifford, David K., Fraenkel, Ernest, Young, Richard A.
Publicado 2004

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

por Brahmer, Julie, Reckamp, Karen L., Baas, Paul, Crinò, Lucio, Eberhardt, Wilfried E.E., Poddubskaya, Elena, Antonia, Scott, Pluzanski, Adam, Vokes, Everett E., Holgado, Esther, Waterhouse, David, Ready, Neal, Gainor, Justin, Frontera, Osvaldo Arén, Havel, Libor, Steins, Martin, Garassino, Marina C., Aerts, Joachim G., Domine, Manuel, Paz-Ares, Luis, Reck, Martin, Baudelet, Christine, Harbison, Christopher T., Lestini, Brian, Spigel, David R.
Publicado en N Engl J Med (2015)

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

por Topalian, Suzanne L., Hodi, F. Stephen, Brahmer, Julie R., Gettinger, Scott N., Smith, David C., McDermott, David F., Powderly, John D., Sosman, Jeffrey A., Atkins, Michael B., Leming, Philip D., Spigel, David R., Antonia, Scott J., Drilon, Alexander, Wolchok, Jedd D., Carvajal, Richard D., McHenry, M. Brent, Hosein, Fareeda, Harbison, Christopher T., Grosso, Joseph F., Sznol, Mario
Publicado en JAMA Oncol (2019)

Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer

por Borghaei, Hossein, Paz-Ares, Luis, Horn, Leora, Spigel, David R., Steins, Martin, Ready, Neal E., Chow, Laura Q., Vokes, Everett E., Felip, Enriqueta, Holgado, Esther, Barlesi, Fabrice, Kohlhäufl, Martin, Arrieta, Oscar, Burgio, Marco Angelo, Fayette, Jérôme, Lena, Hervé, Poddubskaya, Elena, Gerber, David E., Gettinger, Scott N., Rudin, Charles M., Rizvi, Naiyer, Crinò, Lucio, Blumenschein, George R., Antonia, Scott J., Dorange, Cécile, Harbison, Christopher T., Finckenstein, Friedrich Graf, Brahmer, Julie R.
Publicado en N Engl J Med (2015)

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, s...

por Rizvi, Naiyer A, Mazières, Julien, Planchard, David, Stinchcombe, Thomas E, Dy, Grace K, Antonia, Scott J, Horn, Leora, Lena, Hervé, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A, Campos, Luis T, Gandara, David R, Levy, Benjamin P, Nair, Suresh G, Zalcman, Gérard, Wolf, Jürgen, Souquet, Pierre-Jean, Baldini, Editta, Cappuzzo, Federico, Chouaid, Christos, Dowlati, Afshin, Sanborn, Rachel, Lopez-Chavez, Ariel, Grohe, Christian, Huber, Rudolf M, Harbison, Christopher T, Baudelet, Christine, Lestini, Brian J, Ramalingam, Suresh S
Publicado en Lancet Oncol (2015)